Please refer to my article

Michael

Based on my own data, I followed the medicine named

10/25/00  new drup for HBV adefovir

Entecavir was introduced to the mkt/

I talked to Dr. Chen and she told me not good to change from Epivir. Not only because it costs more and the resistance of the body to the new advoir are the quite same. If there is no obvious side effect better stick to Epivir.

I have my blood checked to see if there is any improvement. The on line search engine find another medicine is gone experiment. I will keep an eye on the new development.

Thanks you for your information.

Michael

https://city.udn.com/v1/blog/article/index.jsp?uid=mikkyhan

Epivir-HBV 肝安能 8-Year Follow-Up(32).Beat the Odds. 瀏覽28｜回應0｜推薦0

2006/04/05 09:09:21

“I thought you couldn’t make it!” Momoir.  Part 32. Finally, Beat the Odds. If I can do it, you can do it. I got antibodies <5 present in year 8. I.E. I have recovered. I cannot infect others: Headline News: Mariposa, California, March 21,2006, Michael  may be the 1st HB Patient in the world with lab tested Hepatitis Be antibody <5. According to reliable source,  This is a direct result with patient 8 years continuing oral Epivir manufactured by Glaxosmithkline.  The Lab blood specimen were taken 2/27/2006 and reported 03/01/2006 by the order of Dr. Rose, Robert J conducted by Quest Diagnostics Inc located in John C Fremont Hospital Lab, 5189 Hospital Rd Mariposa CA.95338-9524. In one article dated 4/10/2000 by Dr, Lai in Hong-Kong says:   ” The implication is that monotherapy with just Epivir-HBV alone will not be the ultimate regimen. Neither is monotherapy with alfa interferon, the other FDA-approved drug to treat chronic hepatitis B. Most studies to date have not shown that the addition of alfa interferon to Epivir-HBV is any better than either alone, and that it contributes a significantly worsened side effect profile.”   The above conclusion by Dr. Lai is apparently overturned by this discovery of Michael Han’s lab test results. The above news may cause controversy on the subject matter below:  1.    The patient has been using 75 mg dosage against Epivir 100 mg created for HBV patient only by GLX. 2.    The 1st application for this patient had no doctor’s prescription for a period of one year. 3.  In clinical trials in Japan as of February 1997, All 11 patients required hospitalization. One patient died. 4. Other clinical trials results through out the world have not been provided by GLX. Glaxosmithkine has not provided their own secret file for evaluation to the public. Whether there is any scientist suggestion on providing 75 mg for HBV patient clinical trial, its not known. On consideration of increasing corporate revenue, it is quite possible that 100 mg dosage has been adapted for the sore purpose of profitability. (100mg and 150 mg Epivir at same price.) If you want to check it out your self, here is Glaxo Wellcome's Medical Services Department at (800) 334-0089.  This is sure an encouraging news not only to the 1.25 millions HB patients in the States but possible 300 millions Patients through out the world. The CNN (approached for comments) learned thru friend related to Michael Han, that this patient has contracted HB in his late 40’s in Taiwan. Although he has searched for a complete cure for years and found there is no in the available market. We found that this is a sign that we might be able to have a breakthrough and See the light at end of tunnel for HB patients.